Jupiter NeurosciencesJUNS
NASDAQPharmaceuticals
No cached AI snapshot yet for JUNS.
Be the first to run a multi-agent analysis on this ticker.
Key Stats
5 employees36.28M shares outstandinglisted 2024-12-03
Next earnings ~May 5, 2026
About Jupiter Neurosciences
Jupiter Neurosciences Inc is a clinical-stage research and development company focused on developing treatments for neuroinflammation through the resveratrol platform. Its platform product, JOTROL, is an enhanced oral formulation of resveratrol, which has many potential indications. In the larger disease areas, which are targeting Parkinson's Disease. The group is presently in the process of conducting a Phase IIa clinical trial in Parkinson's Disease. The company operates through two reportable segments: premium nutritional supplements and pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases. It generates the majority of its revenue from Premium Nutritional Supplements, which includes commercialization and sales of the Company's Nugevia product line.
Latest News
Showing market-wide stock news
What history says about longer-term bond yields after the first Fed hike
How The Fed Has Been Quietly Tightening Ahead Of The Expected Rate Hike
Euro: 1.150 target nears on Fed risk against US Dollar – ING
WTI falls near $100 as Saudi adds Oman route, US stocks surge
Yield on 10-year Treasury hovers above 5% as investors await Fed decision
Warsh’s Fed expected to hike rates 25bp as dot plot takes center stage
Related Stocksin Pharmaceuticals
Ready to see the live AI view on JUNS?
Launch a real-time multi-agent room — Claude, GPT, Gemini, DeepSeek, Grok, and Qwen analyzing JUNS side-by-side with live signals.